三诺生物
(300298)
| 流通市值：99.53亿 | | | 总市值：123.35亿 |
| 流通股本：4.55亿 | | | 总股本：5.64亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,041,603,772.08 | 4,443,123,570.61 | 3,182,048,562.89 | 2,133,039,651.44 |
| 营业收入 | 1,041,603,772.08 | 4,443,123,570.61 | 3,182,048,562.89 | 2,133,039,651.44 |
| 二、营业总成本 | 988,932,886.51 | 4,041,229,082.16 | 2,922,130,369.96 | 1,914,280,897.25 |
| 营业成本 | 534,417,807.82 | 2,004,722,409.58 | 1,424,691,749.88 | 956,607,859.95 |
| 税金及附加 | 9,951,649.7 | 44,132,130.82 | 30,718,632.18 | 21,064,901.96 |
| 销售费用 | 289,301,393.26 | 1,191,774,591.77 | 842,261,617.67 | 556,267,169.63 |
| 管理费用 | 76,253,398.4 | 405,530,062.59 | 326,824,721.7 | 204,312,632.89 |
| 研发费用 | 73,478,693.59 | 374,997,672.43 | 278,469,037.83 | 171,174,001.18 |
| 财务费用 | 5,529,943.74 | 20,072,214.97 | 19,164,610.7 | 4,854,331.64 |
| 其中:利息费用 | 9,931,869.94 | 47,465,477.96 | 36,500,349.65 | 24,561,181.65 |
| 其中:利息收入 | 5,367,908.32 | -20,506,208.52 | 15,488,574.73 | 9,840,674.26 |
| 加:投资收益 | -130,675.78 | -1,595,366.95 | -90,742.78 | 706,693.05 |
| 资产处置收益 | -10,984.28 | 957,336.24 | -6,001,488.63 | -3,053,425.35 |
| 资产减值损失(新) | -2,953,281.89 | -74,396,452.82 | -4,578,492.42 | -4,197,429.46 |
| 信用减值损失(新) | 8,105,146.32 | -28,390,059.42 | -22,132,977.44 | -23,853,915.9 |
| 其他收益 | 35,405,935.83 | 100,507,784.2 | 94,045,338.64 | 67,122,422.8 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 93,087,025.77 | 398,977,729.7 | 321,159,830.3 | 255,483,099.33 |
| 加:营业外收入 | 52,016.35 | 644,980.99 | -39,274.11 | 210,951.36 |
| 减:营业外支出 | 91,045.09 | 4,361,528.28 | 2,527,082.93 | 510,013.86 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 93,047,997.03 | 395,261,182.41 | 318,593,473.26 | 255,184,036.83 |
| 减:所得税费用 | 11,686,920.17 | 49,406,583.44 | 46,965,866.72 | 50,352,949.35 |
| 六、净利润 | 81,361,076.86 | 345,854,598.97 | 271,627,606.54 | 204,831,087.48 |
| 持续经营净利润 | 81,361,076.86 | 345,854,598.97 | 271,627,606.54 | 204,831,087.48 |
| 归属于母公司股东的净利润 | 72,115,093.5 | 326,290,993.05 | 255,342,147.59 | 197,485,429.08 |
| 少数股东损益 | 9,245,983.36 | 19,563,605.92 | 16,285,458.95 | 7,345,658.4 |
| (一)基本每股收益 | 0.13 | 0.59 | 0.46 | 0.36 |
| (二)稀释每股收益 | 0.13 | 0.59 | 0.46 | 0.36 |
| 八、其他综合收益 | -7,243,403.27 | 24,447,503.61 | -56,311,165.52 | -20,768,921.79 |
| 归属于母公司股东的其他综合收益 | -5,524,488.46 | 24,206,678.54 | -46,351,970.54 | -18,609,097.48 |
| 九、综合收益总额 | 74,117,673.59 | 370,302,102.58 | 215,316,441.02 | 184,062,165.69 |
| 归属于母公司股东的综合收益总额 | 66,590,605.04 | 350,497,671.59 | 208,990,177.05 | 178,876,331.6 |
| 归属于少数股东的综合收益总额 | 7,527,068.55 | 19,804,430.99 | 6,326,263.97 | 5,185,834.09 |
| 公告日期 | 2025-04-29 | 2025-04-21 | 2024-10-24 | 2024-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |